Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flustop
- Development stage
- Unknown
- Lead developer
- CAPS Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Flustop** is a CAPS Pharmaceuticals oral fixed-dose cold-and-flu symptom-relief capsule marketed in Zimbabwe. The manufacturer lists paracetamol, phenylephrine, and diphenhydramine hydrochloride as active ingredients. Paracetamol provides analgesic and antipyretic activity; phenylephrine is a sympathomimetic nasal decongestant; and diphenhydramine is a sedating first-generation H1 antihistamine intended to relieve allergy-associated symptoms such as sneezing. It is marketed for symptomatic relief of flu and common-cold symptoms rather than as a direct antiviral treatment. ([caps.co.zw](https://caps.co.zw/products/flustop/))
- Brand names
- Flustop
02
Targets
ADOR (Adenosine receptors)ADRA1A (α1A)COXHRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Flustop.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flustop.